NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News → Now Open: Crypto emergency update (From InvestorPlace) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.36▼$14.6350-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume1,766 shsAverage Volume6,668 shsMarket Capitalization$12.92 millionAssets Under Management$20.89 millionDividend Yield2.02%Net Expense Ratio0.79% Stock AnalysisStock AnalysisDividendHeadlinesHoldingsOwnershipRatingsShort InterestSocial MediaStock AnalysisDividendHeadlinesHoldingsOwnershipRatingsShort InterestSocial Media Get Range Cancer Therapeutics ETF alerts: Email Address About Range Cancer Therapeutics ETFThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More Ad InvestorPlaceNow Open: Crypto emergency updateDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. CNCR ETF News HeadlinesMarch 15, 2024 | msn.comLarge-scale study explores genetic link between colorectal cancer and meat intakeMarch 11, 2024 | markets.businessinsider.comMicrobix Unveils Test Controls for Head and Neck CancerApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.March 3, 2024 | nasdaq.comThe Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKBFebruary 22, 2024 | msn.comFDA approval of cancer treatment provides new weapon against tumorsFebruary 21, 2024 | msn.comA watershed moment for cancer therapies has arrivedFebruary 5, 2024 | nz.finance.yahoo.comETF S.S.-LONCAR CAN.I.ETF (E18B.BE)January 24, 2024 | msn.comWhy Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?April 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.January 4, 2024 | markets.businessinsider.comTScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent ProgressSee More Headlines Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings79 Fund Statistics Assets Under Management$20.89 million Average Daily Volume$37,625.90 Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest27,900 shs Miscellaneous Outstanding Shares900,000Beta0.90 Creation Unit50,000 Creation Fee$150.00 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Ad InvestorPlaceNow Open: Crypto emergency updateDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.56%0.54%0.48%0.51%Other Expenses0.00%0.40%0.54%0.34%0.58%Total Expense0.79%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.53%-0.55%-0.22%-0.57%Net Expense0.79%0.60%0.60%0.54%0.58% Range Cancer Therapeutics ETF (CNCR) Holdings & ExposureTop 10 CNCR HoldingsUS DOLLARSHolding Weight: 6.35%Caribou Biosciences(NASDAQ:CRBU)Holding Weight: 1.77%HUTCHMED(NASDAQ:HCM)Holding Weight: 1.65%Recursion Pharmaceuticals(NASDAQ:RXRX)Holding Weight: 1.58%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 1.58%EQRx(NASDAQ:EQRX)Holding Weight: 1.48%Apollomics(NASDAQ:APLM)Holding Weight: 1.45%VectivBio(NASDAQ:VECT)Holding Weight: 1.45%Exscientia(NASDAQ:EXAI)Holding Weight: 1.43%Immunocore(NASDAQ:IMCR)Holding Weight: 1.42%CNCR Sector ExposureCNCR Industry ExposureFull Holdings Details Similar ETFsFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHHorizon Kinetics Medical ETFNASDAQ:MEDXInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQJPMorgan Healthcare Leaders ETFNASDAQ:JDOCProShares UltraShort Nasdaq BiotechnologyNASDAQ:BISInstitutional OwnershipOLD Mission Capital LLCBought 16,319 shares on 2/15/2024Ownership: 1.813%View All Institutional Transactions CNCR ETF - Frequently Asked Questions Are investors shorting Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 27,900 shares, a decline of 59.2% from the March 15th total of 68,300 shares. Based on an average trading volume of 33,000 shares, the days-to-cover ratio is presently 0.8 days. View Range Cancer Therapeutics ETF's Short Interest. What does CNCR invest in? Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $20.89 million assets under management. What stocks does Range Cancer Therapeutics ETF hold? CNCR invests in 79 holdings. Some of the stocks in their portfolio include Caribou Biosciences (CRBU), HUTCHMED (HCM), Recursion Pharmaceuticals (RXRX), Revolution Medicines (RVMD), EQRx (EQRX), Apollomics (APLM), VectivBio (VECT), Exscientia (EXAI), Immunocore (IMCR) and Exelixis (EXEL). What is the management fee for Range Cancer Therapeutics ETF? Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%. What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX). This page (NASDAQ:CNCR) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceThe "Smart Money" Is Ready for May 1st Are You?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.